

## **Tempus**

Tempus is a technology company that is building a library of molecular and clinical data and an operating system to make that data accessible and useful. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine learning platform. It provides genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions.

Overview: Investors:

**Geographic Region:** US Baillie Gifford

Industry: Health T. Rowe Price

Company Website: https://www.tempus.com Revolution

**CEO:** Eric Lefkofsky

New Enterprise Associates

## **Funding Rounds**

Date	Transaction Type	Lead Investors	Capital Raised	Valuation
9/22/2022	Later Stage VC (Series G)	-	\$275.00M	\$10.25B
05/30/2019	Series F	Baillie Gifford	\$200M	\$3.1B (current)
08/29/2018	Series E	Baillie Gifford	\$110M	
03/20/2018	Series D	T. Rowe Price	\$80M	
09/25/2017	Series C	New Enterprise Associates, Revolution	\$70M	